Molecular Partners holds its R&D update in New York, entitled “The DARPin® Difference – Offering Patients a New Dimension of Protein Therapeutics”, which features a series of presentations highlighting the scientific rationale and the potential clinical impact of the DARPin® approach, as well as the company’s continued forward integration and evolution towards becoming a fully integrated biopharmaceutical company.
Read More
